收费全文 | 46558篇 |
免费 | 3478篇 |
国内免费 | 188篇 |
耳鼻咽喉 | 375篇 |
儿科学 | 1506篇 |
妇产科学 | 1200篇 |
基础医学 | 6585篇 |
口腔科学 | 590篇 |
临床医学 | 5031篇 |
内科学 | 9730篇 |
皮肤病学 | 876篇 |
神经病学 | 5540篇 |
特种医学 | 1122篇 |
外科学 | 4149篇 |
综合类 | 380篇 |
一般理论 | 58篇 |
预防医学 | 5665篇 |
眼科学 | 616篇 |
药学 | 2974篇 |
中国医学 | 86篇 |
肿瘤学 | 3741篇 |
2024年 | 59篇 |
2023年 | 650篇 |
2022年 | 1086篇 |
2021年 | 2142篇 |
2020年 | 1297篇 |
2019年 | 1772篇 |
2018年 | 2036篇 |
2017年 | 1361篇 |
2016年 | 1515篇 |
2015年 | 1659篇 |
2014年 | 2024篇 |
2013年 | 2621篇 |
2012年 | 4194篇 |
2011年 | 4149篇 |
2010年 | 2103篇 |
2009年 | 1844篇 |
2008年 | 2942篇 |
2007年 | 2905篇 |
2006年 | 2773篇 |
2005年 | 2568篇 |
2004年 | 2277篇 |
2003年 | 2034篇 |
2002年 | 1731篇 |
2001年 | 193篇 |
2000年 | 142篇 |
1999年 | 208篇 |
1998年 | 347篇 |
1997年 | 260篇 |
1996年 | 212篇 |
1995年 | 175篇 |
1994年 | 124篇 |
1993年 | 118篇 |
1992年 | 68篇 |
1991年 | 65篇 |
1990年 | 55篇 |
1989年 | 56篇 |
1988年 | 49篇 |
1987年 | 37篇 |
1986年 | 38篇 |
1985年 | 34篇 |
1984年 | 46篇 |
1983年 | 44篇 |
1982年 | 33篇 |
1981年 | 41篇 |
1980年 | 28篇 |
1979年 | 17篇 |
1978年 | 13篇 |
1977年 | 20篇 |
1975年 | 9篇 |
1973年 | 8篇 |
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献The metabolism of the pyrethroids deltamethrin (DLM), cis-permethrin (CPM) and trans-permethrin (TPM) was studied in human expressed cytochrome P450 (CYP) and carboxylesterase (CES) enzymes.
DLM, CPM and TPM were metabolised by human CYP2B6 and CYP2C19, with the highest apparent intrinsic clearance (CLint) values for pyrethroid metabolism being observed with CYP2C19. Other CYP enzymes contributing to the metabolism of one or more of the three pyrethroids were CYP1A2, CYP2C8, CYP2C9*1, CYP2D6*1, CYP3A4 and CYP3A5. None of the pyrethroids were metabolised by CYP2A6, CYP2E1, CYP3A7 or CYP4A11.
DLM, CPM and TPM were metabolised by both human CES1 and CES2 enzymes.
Apparent CLint values for pyrethroid metabolism by CYP and CES enzymes were scaled to per gram of adult human liver using abundance values for microsomal CYP enzymes and for CES enzymes in liver microsomes and cytosol. TPM had the highest and CPM the lowest apparent CLint values for total metabolism (CYP and CES enzymes) per gram of adult human liver.
Due to their higher abundance, all three pyrethroids were extensively metabolised by CES enzymes in adult human liver, with CYP enzymes only accounting for 2%, 10% and 1% of total metabolism for DLM, CPM and TPM, respectively.